AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS	3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS	NOTE 15 – AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS In preparing the interim condensed consolidated financial statements for the three and six months ended June 30, 2025, the Company identified an error in the accounting for a warrant modification originally reported in the interim condensed consolidated financial statements for the three months ended March 31, 2025. The Company had incorrectly recorded $623 as warrant modification expense within “Other Expense” rather than within equity. ENVUE MEDICAL, INC. Notes to the Interim Condensed Consolidated Financial Statements (unaudited) (Amounts in thousands except share and per share data) The Company evaluated the materiality of the error and concluded that the correction would not be material to the financial position or results of operations for the three months ended March 31, 2025. The impact of the error on the Company’s interim condensed consolidated financial statements for the three months ended March 31, 2025 was as follows: (i) warrant modification expense within Other Expense was overstated by $623, resulting in an overstatement of net loss of $623; (ii) accumulated deficit was overstated by $623 as a result of the overstatement of net loss; (iii) additional paid-in capital was understated by $623; and (iv) the error had no impact on cash flows from operating, investing, or financing activities.

AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS

NOTE 15 – AN IMMATERIAL ERROR IN PRIOR-PERIOD FINANCIAL STATEMENTS

In preparing the interim condensed consolidated financial statements for the three and six months ended June 30, 2025, the Company identified an error in the accounting for a warrant modification originally reported in the interim condensed consolidated financial statements for the three months ended March 31, 2025. The Company had incorrectly recorded $623 as warrant modification expense within “Other Expense” rather than within equity.

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(Amounts in thousands except share and per share data)

The Company evaluated the materiality of the error and concluded that the correction would not be material to the financial position or results of operations for the three months ended March 31, 2025.

The impact of the error on the Company’s interim condensed consolidated financial statements for the three months ended March 31, 2025 was as follows: (i) warrant modification expense within Other Expense was overstated by $623, resulting in an overstatement of net loss of $623; (ii) accumulated deficit was overstated by $623 as a result of the overstatement of net loss; (iii) additional paid-in capital was understated by $623; and (iv) the error had no impact on cash flows from operating, investing, or financing activities.